TrialScientific reports2021

Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis.

Lixin Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.